P53 ANTIBODIES IN THE SERA OF LUNG-CANCER PATIENTS - COMPARISON WITH P53 MUTATION IN THE TUMOR-TISSUE

被引:93
作者
WILD, CP
RIDANPAA, M
ANTTILA, S
LUBIN, R
SOUSSI, T
HUSGAFVELFURSIAINEN, K
VAININO, H
机构
[1] INST OCCUPAT HLTH,HELSINKI,FINLAND
[2] INST GENET MOLEC,INSERM,U301,PARIS,FRANCE
关键词
D O I
10.1002/ijc.2910640306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study examined the sensitivity and specificity of serum auto-antibodies to p53 protein as a non-invasive marker of p53 genetic alterations or protein accumulation in lung cancer cases. A sensitive ELISA to detect serum p53 antibodies was developed and used to examine sera from 186 patients undergoing pulmonary surgery for a suspected lung cancer. Target antigens in ELISA were wild-type p53 protein and 5 peptides covering the N- and C-terminal parts of the protein. Sixteen sera were positive for serum p53 antibodies in both ELISAs and all were among the 136 patients with confirmed primary lung carcinoma. Of 50 patients with other pulmonary diseases, none had p53 antibodies. In 92 cancer patients exons 5 to 8 of the p53 gene were examined for mutations by denaturing gradient gel electrophoresis and direct sequencing of PCR products. Forty-seven tumours had a p53 mutation and 7 (15.2%) of these were positive for p53 antibodies. Two patients had serum antibodies but no detectable mutation in exons 5 to 8. Frequencies of p53 mutations and serum antibodies were higher in squamous cell carcinoma patients than in adenocarcinoma. Accumulation of p53 protein in tumour tissue was observed in 32 patients, but only 5 were positive for p53 antibodies. In conclusion, serum p53 antibodies were detected only in a proportion of lung cancer cases, but the majority were specifically associated with a detectable p53 mutation in the tumour. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:176 / 181
页数:6
相关论文
共 20 条
[1]  
ANGELOPOULOU K, 1993, CANCER J - FRANCE, V6, P315
[2]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263
[3]  
Chapot B., 1991, TECHNIQUES DIAGNOSTI, P135
[4]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[5]   DETECTION OF ANTIBODIES AGAINST THE CELLULAR PROTEIN P53 IN SERA FROM PATIENTS WITH BREAST-CANCER [J].
CRAWFORD, LV ;
PIM, DC ;
BULBROOK, RD .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (04) :403-408
[6]   IMMUNE-RESPONSE TO P53 IS DEPENDENT UPON P53/HSP70 COMPLEXES IN BREAST CANCERS [J].
DAVIDOFF, AM ;
IGLEHART, JD ;
MARKS, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3439-3442
[7]   PRESENCE OF CIRCULATING ANTIBODIES AGAINST CELLULAR PROTEIN P53 IN A NOTABLE PROPORTION OF CHILDREN WITH B-CELL LYMPHOMA [J].
DEFROMENTEL, CC ;
MAYLEVIN, F ;
MOURIESSE, H ;
LEMERLE, J ;
CHANDRASEKARAN, K ;
MAY, P .
INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (02) :185-189
[8]  
HALL PA, 1993, ONCOGENE, V8, P203
[9]  
HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551
[10]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53